Dr. Markman on the Future of Treatment for Ovarian Cancer

Maurie Markman, MD
Published: Monday, Apr 13, 2015



Maurie Markman, MD, national director, Cancer Treatment Centers of America, discusses what he sees as future treatment paradigms in ovarian cancer.

The two areas Markman sees as becoming more prominent in ovarian cancer are more effective targeted therapies and immunotherapy. In regards to targeted therapies, he thinks researchers will focus on molecular abnormalities, specifically in RNA and proteins. This process includes finding the targets, tumor weaknesses, driver mutations, and discovering the appropriate agent(s). Through those steps, Markman says the course of the disease should be followed through liquid tumor biopsies.

Immunotherapy will likely play a significant role in treatment in the future. Though the concept of immunotherapy had been around for several decades, Markman explains researchers did not understand the biology of cancer cells, nor did they have the current agents available. However, that is rapidly changing, and evidence of promising treatment outcomes with immunotherapy is beginning to show in ovarian, cervical and endometrial cancers, Markman adds.



Maurie Markman, MD, national director, Cancer Treatment Centers of America, discusses what he sees as future treatment paradigms in ovarian cancer.

The two areas Markman sees as becoming more prominent in ovarian cancer are more effective targeted therapies and immunotherapy. In regards to targeted therapies, he thinks researchers will focus on molecular abnormalities, specifically in RNA and proteins. This process includes finding the targets, tumor weaknesses, driver mutations, and discovering the appropriate agent(s). Through those steps, Markman says the course of the disease should be followed through liquid tumor biopsies.

Immunotherapy will likely play a significant role in treatment in the future. Though the concept of immunotherapy had been around for several decades, Markman explains researchers did not understand the biology of cancer cells, nor did they have the current agents available. However, that is rapidly changing, and evidence of promising treatment outcomes with immunotherapy is beginning to show in ovarian, cervical and endometrial cancers, Markman adds.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x